EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adenosine-generating CD39 + plasmablasts predispose to successful infliximab therapy in pediatric IBD

Alexander Schnell iD, Benedikt Schwarz, Hannah Schmidt, Ida Allabauer, Wolfgang Schuh, Adrian P Regensburger iD, Manfred Rauh iD, Joachim Woelfle iD, André Hoerning iD

Life Science Alliance · 2025-06 · 8 (6) · e202403055

DOI: 10.26508/lsa.202403055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 08.04.2025. Verfasst von Alexander Schnell und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology and Hepatology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-Univer…. Hauptthemen laut MEDLINE: Apyrase, Infliximab, Adenosine, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johannes-und-Frieda-Marohn-Stiftung, IZKF Erlangen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B cells display several immunoregulatory mechanisms including the production of interleukin-10. Ectonucleotidases like CD39 and CD73 influence immune homeostasis by metabolizing eATP and generating immunosuppressive adenosine. The major objective was to examine the expression of those immunoregulatory molecules on B-cell subsets, and, more specifically, to determine their association with an infliximab (IFX) treatment in a pediatric inflammatory bowel disease (IBD) cohort. 42 IBD patients were assessed for IFX response after 12 mo of therapy and compared against 14 healthy controls (HC). Although IL10-producing plasmablasts were decreased in IFX nonresponders (NRS), we detected an up-regulation of CD39 on plasmablasts and increased fractions of CD39/CD73-co-expressing naïve and memory B cells in responding patients (RS). In addition, B cells of responders proved to have superior ATP degradation capacities and adenosine production before therapy initiation compared with NRS and HC. Moreover, IFX nonresponders had a marked deficiency of α4β7hi plasmablasts, whereas both cohorts had fewer CCR9-expressing plasmablasts. Consequently, CD39 + plasmablasts were decreased in biopsies of inflamed mucosal tissues, especially in IFX nonresponders. Our results highlight the regulatory potential of CD39/CD73-expressing B cells in pediatric IBD and suggest CD39 + plasmablasts as a potential determinant of a successful immunosuppressive therapy with IFX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApyraseInfliximabAdenosineInflammatory Bowel DiseasesAntigens, CDPlasma CellsHumansChildMaleFemaleAdolescent5'-NucleotidaseInterleukin-10B-LymphocytesGPI-Linked Proteins

Substanzen

ApyraseInfliximabAdenosine5'-NucleotidaseAntigens, CDCD39 antigenInterleukin-10ENTPD1 protein, humanNT5E protein, humanGPI-Linked Proteins

Autor:innen und Institutionen

  • Pediatric Gastroenterology and Hepatology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany alexander.schnell@uk-erlang…
  • Pediatric Gastroenterology and Hepatology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Division of Molecular Immunology, Department of Internal Medicine III, Nikolaus-Fiebiger Center, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.

ORCID-Profile: Alexander Schnell, Adrian P Regensburger, Manfred Rauh, Joachim Woelfle, André Hoerning

Förderung

  • Johannes-und-Frieda-Marohn-Stiftung
  • IZKF Erlangen

Zitieren

APA

Schnell, A., Schwarz, B., Schmidt, H., Allabauer, I., Schuh, W., Regensburger, A. P., Rauh, M., Woelfle, J., & Hoerning, A. (2025). Adenosine-generating CD39 + plasmablasts predispose to successful infliximab therapy in pediatric IBD. Life Science Alliance, 8(6), e202403055. https://doi.org/10.26508/lsa.202403055

Vancouver

Schnell A, Schwarz B, Schmidt H, Allabauer I, Schuh W, Regensburger AP, et al. Adenosine-generating CD39 + plasmablasts predispose to successful infliximab therapy in pediatric IBD. Life Science Alliance. 2025;8(6):e202403055. doi:10.26508/lsa.202403055

BibTeX
@article{Schnell2025,
  author = {Schnell, Alexander and Schwarz, Benedikt and Schmidt, Hannah and Allabauer, Ida and Schuh, Wolfgang and Regensburger, Adrian P and Rauh, Manfred and Woelfle, Joachim and Hoerning, André},
  title = {Adenosine-generating CD39 + plasmablasts predispose to successful infliximab therapy in pediatric IBD},
  journal = {Life Science Alliance},
  year = {2025},
  volume = {8},
  number = {6},
  pages = {e202403055},
  doi = {10.26508/lsa.202403055}
}
Kostenlos starten →